Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T40281 |
KRAS G12D inhibitor 6
|
||
KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D. | |||
T11773 |
KRAS inhibitor-6
|
Ras | GPCR/G Protein; MAPK |
KRAS inhibitor-6 is a potent KRAS G12C inhibitor. | |||
T3725 |
K-Ras(G12C) Inhibitor 6
|
Raf | MAPK |
KRas(G12C) inhibitor 6 是一种变构的,选择性的 K-Ras(G12C)抑制剂。 | |||
T12979 |
BI-3406
|
p38 MAPK; MAPK; Ras | GPCR/G Protein; MAPK |
BI-3406 是一种可口服、高效且选择性的 KRAS-SOS1 抑制剂,具有抗癌活性。它有效减少 GTP 加载的 KRAS 的形成,抑制 MAPK 信号通路。它还抑制 KRAS 与 SOS1之间相互作用,IC50为 6 nM。 | |||
T6878 |
LJI308
|
S6 Kinase | MAPK; PI3K/Akt/mTOR signaling |
LJI308 是泛RSK 抑制剂,对 RSK1、RSK2 和 RSK3 的IC50分别为 6、4 和 13 nM。它抑制辐照、EGF 处理和表达 KRAS 突变的细胞中 RSK (T359/S363) 和 YB-1 (S102) 的磷酸化。 | |||
T63164 | KRAS inhibitor-13 | ||
KRAS inhibitor-13 (compound 5-6) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.883 μM)。KRAS inhibitor-13 在 MIA PaCA-2,A549 细胞中具有 p-ERK 抑制效果,其 IC50 值分别为 5.9,>100 μM。 KRAS inhibitor-13 具有潜力进行胰腺癌、结直肠癌和肺癌的研究。 | |||
T62751 | KRAS inhibitor-12 | ||
KRAS inhibitor-12 (compound 6-1) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.537 μM)。KRAS inhibitor-12 在 MIA PaCA-2,A549 细胞中表现出 p-ERK 抑制作用,其 IC50 值分别为 1.3,3.7 μM。 KRAS inhibitor-12 具有潜力进行胰腺癌,结直肠癌和肺癌的研究。 | |||
T79800 |
pan-KRAS-IN-2
|
Ras | GPCR/G Protein; MAPK |
Pan-KRAS-IN-2(compound 6)是一种抑制剂,对KRAS WT及其多种突变体(G12D、G12C、G12V、G12S、G12A、Q61H)表现出极高的抑制活性,其IC50均不超过10 nM;然而对KRAS G13D的抑制活性较低,IC50超过10 μM。 | |||
T72356 |
KRAS G12C inhibitor 56
|
||
KRAS G12C inhibitor 56(化合物IC-6),作为一种SOS1抑制剂,显示出1.6 nM的IC50值,表明其对于癌症研究的潜在应用价值。 | |||
T36676 |
Rineterkib hydrochloride
|
||
Rineterkib hydrochloride (compound B) is an orally active RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer[1]. ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the C... |